BTK and B-cell chronic lymphocytic leukemia: The introduction of the covalent Bruton’s tyrosine kinase (BTK) inhibitors ibrutinib, acalabrutinib, and zanubrutinib has revolutionized the treatment paradigm and improved outcomes for patients with advanced chronic lymphocytic leukemia (CLL) [1,2,3,4,5,6,7,8,9].